Immunophotonics, Inc.
Immunophotonics is dedicated to developing proprietary technology in the field of Interventional Immuno-Oncology™. The company's mission is to advance breakthrough drug discoveries and transform standard treatments into powerful immunotherapies, aiming to improve patient outcomes worldwide. Their vision involves a multimodal approach that elevates modern medicine, enabling routine treatments to provide enhanced results. The company actively collaborates with top universities and research institutions globally, and maintains a strong pipeline of patents supporting innovative off-the-shelf therapies for cancer treatment. Immunophotonics also emphasizes compliance with financial conflict of interest policies and maintains transparency through public posting and detailed procedures for managing conflicts, especially in federally funded projects.
Industries
Nr. of Employees
small (1-50)
Immunophotonics, Inc.
Products
Clinical-stage glycan polymer immunostimulant
A clinical-stage polymer material formulated for local injection into ablated or irradiated tumor tissue to bind liberated antigens, enhance antigen uptake by antigen-presenting cells, and promote systemic anti-tumor T-cell responses.
Clinical-stage glycan polymer immunostimulant
A clinical-stage polymer material formulated for local injection into ablated or irradiated tumor tissue to bind liberated antigens, enhance antigen uptake by antigen-presenting cells, and promote systemic anti-tumor T-cell responses.
Services
Clinical trial collaborations and execution
Design and support of investigator- and sponsor-led clinical studies combining local interventional procedures with locally delivered immunostimulants at academic medical centers.
Partnership development and commercialization support
Strategic collaborations with medical device manufacturers, clinical networks, and investors to advance combination interventional-immunotherapy programs toward clinical evaluation and commercialization.
Government-award compliance and FCOI support
Implementation and administration of financial conflict-of-interest policies for PHS-funded awards, including investigator training, disclosure workflows, external partner verification, report preparation, and record retention.
Clinical trial collaborations and execution
Design and support of investigator- and sponsor-led clinical studies combining local interventional procedures with locally delivered immunostimulants at academic medical centers.
Partnership development and commercialization support
Strategic collaborations with medical device manufacturers, clinical networks, and investors to advance combination interventional-immunotherapy programs toward clinical evaluation and commercialization.
Government-award compliance and FCOI support
Implementation and administration of financial conflict-of-interest policies for PHS-funded awards, including investigator training, disclosure workflows, external partner verification, report preparation, and record retention.
Expertise Areas
- Interventional immuno-oncology (integration of local tumor disruption with immunotherapy)
- Oncology clinical trial design and execution (early- and mid-stage)
- Polymer-based immunoadjuvant development
- Translational immunology and mechanism-of-action research
Key Technologies
- Polymer-based immunostimulants (glycan polymers)
- Intratumoral delivery techniques
- Thermal ablation and irreversible electroporation
- Antigen capture and presentation enhancement